What Happened
The FDA has issued a warning letter to Whoop, a popular health tech company, over its blood pressure feature, which has sparked controversy. According to a top executive, the company is in discussions with the FDA to resolve the issue. Meanwhile, an investigation by the BBC has uncovered that councils are paying up to £2m per child to unregistered children's homes, which are often substandard and unregulated.
Why It Matters
The FDA's actions against Whoop highlight the need for stricter regulation of health tech companies, which are increasingly collecting sensitive health data from consumers. The controversy surrounding Whoop's blood pressure feature raises questions about the accuracy and reliability of health data collected by wearable devices.
The Dark Side of Health Tech Regulation
According to Paul Knoepfler, a columnist for STAT+, the FDA is facing dark times ahead, with the Trump administration's policies undermining the agency's ability to regulate the industry effectively.
What Experts Say
"The FDA needs to take a more proactive approach to regulating health tech companies, rather than just reacting to controversies after they arise." — Paul Knoepfler, STAT+ columnist
Key Numbers
- ****£2m:** The amount councils are paying per child to unregistered children's homes
- **13,000: The weekly cost of caring for a vulnerable teenage girl in an unregistered children's home
- **42%: The percentage of children's homes that are unregistered, according to a 2020 report
Background
The use of unregistered children's homes has been a long-standing issue in the UK, with many homes operating outside of regulatory frameworks. In 2018, the government banned the use of unregulated children's homes in England, but the practice continues, with many homes operating in secret.
What Comes Next
The FDA's actions against Whoop and the investigation into unregistered children's homes highlight the need for greater transparency and regulation in the health tech and childcare industries. As the UK government considers new regulations to crack down on unregistered children's homes, the FDA must also take a more proactive approach to regulating health tech companies.
Key Facts
- Who: Whoop, a health tech company
- What: FDA warning letter over blood pressure feature
- When: Discussions between Whoop and FDA are ongoing
- Impact: Greater scrutiny of health tech companies and unregistered children's homes
What to Watch
As the FDA and UK government take steps to regulate the health tech and childcare industries, consumers and parents must remain vigilant, demanding greater transparency and accountability from companies and institutions.
What Happened
The FDA has issued a warning letter to Whoop, a popular health tech company, over its blood pressure feature, which has sparked controversy. According to a top executive, the company is in discussions with the FDA to resolve the issue. Meanwhile, an investigation by the BBC has uncovered that councils are paying up to £2m per child to unregistered children's homes, which are often substandard and unregulated.
Why It Matters
The FDA's actions against Whoop highlight the need for stricter regulation of health tech companies, which are increasingly collecting sensitive health data from consumers. The controversy surrounding Whoop's blood pressure feature raises questions about the accuracy and reliability of health data collected by wearable devices.
The Dark Side of Health Tech Regulation
According to Paul Knoepfler, a columnist for STAT+, the FDA is facing dark times ahead, with the Trump administration's policies undermining the agency's ability to regulate the industry effectively.
What Experts Say
"The FDA needs to take a more proactive approach to regulating health tech companies, rather than just reacting to controversies after they arise." — Paul Knoepfler, STAT+ columnist
Key Numbers
- ****£2m:** The amount councils are paying per child to unregistered children's homes
- **13,000: The weekly cost of caring for a vulnerable teenage girl in an unregistered children's home
- **42%: The percentage of children's homes that are unregistered, according to a 2020 report
Background
The use of unregistered children's homes has been a long-standing issue in the UK, with many homes operating outside of regulatory frameworks. In 2018, the government banned the use of unregulated children's homes in England, but the practice continues, with many homes operating in secret.
What Comes Next
The FDA's actions against Whoop and the investigation into unregistered children's homes highlight the need for greater transparency and regulation in the health tech and childcare industries. As the UK government considers new regulations to crack down on unregistered children's homes, the FDA must also take a more proactive approach to regulating health tech companies.
Key Facts
- Who: Whoop, a health tech company
- What: FDA warning letter over blood pressure feature
- When: Discussions between Whoop and FDA are ongoing
- Impact: Greater scrutiny of health tech companies and unregistered children's homes
What to Watch
As the FDA and UK government take steps to regulate the health tech and childcare industries, consumers and parents must remain vigilant, demanding greater transparency and accountability from companies and institutions.